Journal
NATURE REVIEWS CANCER
Volume 6, Issue 10, Pages 813-823Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc1951
Keywords
-
Categories
Ask authors/readers for more resources
The US National Cancer Institute (NCl) 60 human tumour cell line anticancer drug screen (NCl60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available